Teva Settles With BMS, Merck Over HIV Drug Generic Plans

Law360, New York (June 6, 2013, 5:03 PM EDT) -- Teva Pharmaceuticals Industries Ltd. on Wednesday agreed to a settlement with Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp., ending claims in New York federal court that its planned generic version of HIV treatment Atripla had infringed two patents.

According to an order issued by U.S. District Judge Richard J. Sullivan, dismissing the case without prejudice, the parties have reached a tentative settlement deal, avoiding a trial which was due to start later this month. Further details of the settlement deal weren’t available.

A representative...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.